Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

Breast Cancer (BC) is a highly prevalent disease. A woman living in the United States has a 12.3% lifetime risk of being diagnosed with breast cancer [1]. It is the most common female cancer and the second most common cause of cancer death in women [2]. Of note, amplification or overexpression of Hu...

Descripción completa

Detalles Bibliográficos
Autores principales: de Melo Gagliato, Debora, Leonardo Fontes Jardim, Denis, Marchesi, Mario Sergio Pereira, Hortobagyi, Gabriel N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325455/
https://www.ncbi.nlm.nih.gov/pubmed/26824988
http://dx.doi.org/10.18632/oncotarget.7043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325455/
https://www.ncbi.nlm.nih.gov/pubmed/26824988
http://dx.doi.org/10.18632/oncotarget.7043

Ejemplares similares